Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$250.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Venus Remedies Ltd Receives Nod For Four Plants From Australian Authority-The Economic Times


Thursday, 14 Feb 2013 06:34am EST 

The Economic Times reported that Venus Remedies Ltd has received approval from Australian authorities for four of facilities, thus enabling the Company to export products from these facilities to Australia. The Company has received Good Manufacturing Practices (GMP) approval from Therapeutic Goods Administration (TGA) Australia for four of facilities - Cephalosporin, Carapenems, and Oncology liquid and Oncology lyophilised, Venus Remedies said in a statement. Venus has already filed dossier for meropenem which is on the verge of registration and TGA approval of facility will further expedite the process, it added. 

Company Quote

266.9
-7.15 -2.61%
6:26am EDT